Biopharma · FDA Approvals · Stock

ALMS Alumis

Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer th…

Assets on file: envudeucitinib

Catalyst calendar

Dated catalysts for ALMS, including recently decided ones.

Recent first-hand events

Every first-hand event for ALMS, newest first.

Instant stream — events appear as soon as they are filed.
Decision-gradeMaterialNotableMinor
Aug 13, 2026
08:07 PM
ALMSAlumis

Alumis: ONWARD3 shows 54% PASI 100 at 48 weeks for envudeucitinib

The ONWARD3 long-term extension data demonstrate that 54% of patients achieved complete skin clearance (PASI 100) and 75% achieved PASI 90 after up to 48 weeks of continuous treatment, reinforcing the Phase 3 topline results and supporting the planned NDA submission in Q4 2026.

Topline resultsSEC 8-KOpen record5 updates

Peers by market cap

Companies in the same sector closest to ALMS in market value.

ALMS FDA Calendar & Catalysts — Alumis | Biopharma · FDA Approvals | SimianX AI